U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H28N4O3.H2O4S
Molecular Weight 482.551
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIXAZINONE SULFATE ANHYDROUS

SMILES

OS(O)(=O)=O.CN(C1CCCCC1)C(=O)CCCOC2=CC=C3NC4=NC(=O)CN4CC3=C2

InChI

InChIKey=QWZIAYHPUVIQMT-UHFFFAOYSA-N
InChI=1S/C21H28N4O3.H2O4S/c1-24(16-6-3-2-4-7-16)20(27)8-5-11-28-17-9-10-18-15(12-17)13-25-14-19(26)23-21(25)22-18;1-5(2,3)4/h9-10,12,16H,2-8,11,13-14H2,1H3,(H,22,23,26);(H2,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H28N4O3
Molecular Weight 384.472
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Lixazinone selectively inhibits the high-affinity form of cyclic AMP phosphodiesterase (type IV) isolated from human platelets with only weak effects on both the nonspecific and cyclic GMP-sensitive phosphodiesterases. The inhibitor reduces both maximum velocity and substrate affinity of the type IV enzyme. Lixazinone exhibits marked selectively for the platelet high-affinity enzyme. It also has significant inhibitory effects on cardiac membrane-bound phosphodiesterase. Lixazinone may be useful as an agent to increase cardiac output in the treatment of congestive heart failure. It is a potent PDE3 inhibitor. Lixazinone suppresses folic acid-induced proliferation of rat tubular epithelial cells in vivo.

Approval Year

PubMed

PubMed

TitleDatePubMed
A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
1986 Jun
RS-82856, a selective phosphodiesterase inhibitor with inotropic, afterload reduction and antithrombotic properties.
1987
Electrochemical evaluation of the interaction between ascorbic acid and the cardiotonic drug RS-82856.
1987 Dec
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).
1987 Feb
Parenteral formulation development for the positive inotropic agent RS-82856: solubility and stability enhancement through complexation and lyophilization.
1987 Jul-Aug
Inhibitors of cyclic AMP phosphodiesterase. 4. Synthesis and evaluation of potential prodrugs of lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide, RS-82856).
1988 Nov
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.
1988 Nov
Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]LY186126 in ventricular myocardium.
1989 Aug
Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
1994 Jun 15
Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells.
1995 Jul
Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV.
1996 Jul 15
Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets.
1997 Apr 1
Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis.
1997 Apr 11
Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid.
1997 Nov
Signaling role of PDE isozymes in pathobiology of glomerular mesangial cells. Studies in vitro and in vivo.
1998
Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms.
2000 Apr 21
Lixazinone stimulates mitogenesis of Madin-Darby canine kidney cells.
2006 Mar
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:39:49 GMT 2023
Edited
by admin
on Sat Dec 16 01:39:49 GMT 2023
Record UNII
OW125J77XM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LIXAZINONE SULFATE ANHYDROUS
Common Name English
BUTANAMIDE, N-CYCLOHEXYL-N-METHYL-4-((1,2,3,5-TETRAHYDRO-2-OXOIMIDAZO(2,1-B)QUINAZOLIN-7-YL)OXY)-, SULFATE (1:1)
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID70148605
Created by admin on Sat Dec 16 01:39:49 GMT 2023 , Edited by admin on Sat Dec 16 01:39:49 GMT 2023
PRIMARY
PUBCHEM
135565728
Created by admin on Sat Dec 16 01:39:49 GMT 2023 , Edited by admin on Sat Dec 16 01:39:49 GMT 2023
PRIMARY
FDA UNII
OW125J77XM
Created by admin on Sat Dec 16 01:39:49 GMT 2023 , Edited by admin on Sat Dec 16 01:39:49 GMT 2023
PRIMARY
CAS
108609-34-3
Created by admin on Sat Dec 16 01:39:49 GMT 2023 , Edited by admin on Sat Dec 16 01:39:49 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SOLVATE->ANHYDROUS
Related Record Type Details
ACTIVE MOIETY